Antiviral Drugs Market to Grow at 3.2% CAGR from 2019 to 2026; Hospital Pharmacies to Gain Traction Driven by Strong Government Support
The global
antiviral drugs market size stood at USD
36.1 billion in 2018 and is projected to reach USD 44.2 billion by 2026, exhibiting a CAGR of 3.2% over 2019 to 2026. The rise can be attributed to the growing
development of novel therapies by several pharmaceutical companies.
Combination Drugs Segment to Register Notable
Surge Driven by Growing Launch of New Therapies
On the
basis of drug class, the industry is categorized into reverse transcriptase
inhibitors, protease inhibitors, integrase inhibitors, combination drugs, polymerase
inhibitors, and others. Of these, the combination drugs segment is anticipated
to record commendable expansion over the forecast period owing to the rising
launch of new therapies. Based on region, the market is subdivided into Europe,
Asia Pacific, South America, North America, and the Middle East & Africa.
Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antiviral-drugs-market-102190
Key Industry Development:
June 2021 – Vaxart,
Inc., inked a licensing deal with Altesa Biosciences Inc. The agreement is
intended at granting Altesa the right to develop and produce Vaxart’s formulation
of Vapendavir.
List of Key Players Mentioned in the Report:
·
Janssen Pharmaceuticals, Inc.
·
Abbvie, Inc.
·
Mylan N.V.
·
Gilead Sciences
·
Novartis AG
·
Bristol-Myers Squibb Company
·
GlaxoSmithKline
·
Merck & Co., Inc.
HIV Segment to Record Substantial Growth Owing to
Favorable Reinforcement Policies in Several Countries
Based on disease
indication, the market is segmented into influenza, human immunodeficiency
virus (HIV), hepatitis, and others. The HIV segment is slated to register
lucrative growth over the estimated period. The escalation can be credited to a
rise in favorable reimbursement policies and the incidences of HIV infection in
many countries.
Report Coverage:
The report
provides an in-depth analysis of the key trends that are slated to drive
industry expansion over the forthcoming years. It further gives an insight into
the significant trends that are poised to impel the business landscape across
various regions. The report also gives an account of the critical steps taken
by major industry players for strengthening their position in the market.
Drivers and Restraints:
Industry Value to Rise Driven by Growing Burden
of HIV Infection
HIV infection
is considered as the most common form of viral infection at the global level.
Antiviral drugs market growth can be attributed to the improved rate of disease
diagnosis on account of biological and demographic data. The demand for
specific and targeted treatment regimens is boosted by the escalating burden of
this infection.
However,
long-acting antiviral drugs have certain disadvantages including implementation
challenges, uncertain costing, and complex delivery. These factors are likely
to hinder industry expansion to some extent.
About Us:
Fortune
Business Insights™ offers expert corporate analysis and accurate data, helping
organizations of all sizes make timely decisions. We tailor innovative
solutions for our clients, assisting them address challenges distinct to their
businesses. Our goal is to empower our clients with holistic market intelligence,
giving a granular overview of the market they are operating in. Our reports
contain a unique mix of tangible insights and qualitative analysis to help
companies achieve sustainable growth. Our team of experienced analysts and
consultants use industry-leading research tools and techniques to compile
comprehensive market studies, interspersed with relevant data.
Contact Us:
Fortune
Business Insights Pvt. Ltd.
9th Floor,
Icon Tower, Baner - Mahalunge Road,
Baner,
Pune-411045,
Maharashtra,
India.
Phone:
US :+1 424
253 0390
UK : +44
2071 939123
APAC : +91
744 740 1245
Email:
mailto:sales@fortunebusinessinsights.com
Comments
Post a Comment